An interventional study of Care pathway in Sickle Cell Crisis, sponsored by Medical College of Wisconsin. Recruiting at 1 site in United States. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2023-08-14.
Sponsored by Medical College of Wisconsin · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Vaso-Occlusive Crises with a site in United States — 13 open to participants now, 15 under way, 5 of them phase 3. Vaso-Occlusive Crises · United States.
Among the 60 studies in Vaso-Occlusive Crises with a site in United States, this one has the largest planned enrollment of the 56 interventional ones that give a count, is one of 6 that started in 2021, is one of 9 with no phase, reaches primary completion later than 3 of the 14 other live ones, and was the 47th registered.
104 studies on the registry are indexed under Vaso-Occlusive Crises; 31 are open to participants now.
Browse Vaso-Occlusive Crises studies →13 of the 60 studies in Vaso-Occlusive Crises with a site in United States are open now. Recruiting first, the newest first:
University of Maryland, Baltimore · Sites in United States
Ages 18–88
Mohsen Saidinejad · Sites in United States
Ages 5–20
CSL Behring · Sites in United States, Belgium, France and 4 more countries
Ages 18+
CSL Behring · Sites in United States, Turkey, United Kingdom
Ages 12+
Novartis Pharmaceuticals · Sites in United States, Brazil, Colombia and 2 more countries
Ages 12–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Vaso-Occlusive Crises studies recruiting now, 7 (41%) set no upper age limit and 6 (35%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.
This study: Up to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 20 · Phase 3 17 · Phase 4 6
First in 2000; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,328 is above the median of 81 across 86 interventional studies indexed under Vaso-Occlusive Crises.
Median enrollment 63 across the 56 interventional studies, 82 across the 4 observational. Of the 41 that completed or were terminated, 22 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 60 have an industry lead sponsor. The 10 most frequent:
Medical College of Wisconsin is the lead sponsor of 550 studies on the registry; 123 are open to participants now.
Of its 76 completed or terminated interventional studies of FDA-regulated products, 58 (76%) have results posted.
Medical College of Wisconsin has 1 study filed under Vaso-Occlusive Crises — fewer than ten, so there is no comparison to draw.
3 of the studies in Vaso-Occlusive Crises with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06989567Phase 3Asklepion Pharmaceuticals, LLCA Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis | 2027-06 |
| NCT03353584St. Jude Children's Research HospitalEffect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease | 2026-11 |
| NCT06699849CSL BehringSafety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis | 2027-10-22 |
Add all 3 to your calendar (.ics) → With an account.
Among the 60 studies in Vaso-Occlusive Crises with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sickle cell disease (SCD) is an inherited blood disorder affecting approximately 36,000 children in the United States, approximately 90% of whom are Black. The disease is characterized by recurrent, severe pain crises which result in high rates of emergency department visits and hospitalizations, and decreased quality of life. The National Heart, Lung and Blood Institute, as well as the American Society of Hematology, have endorsed pain management guidelines regarding the timeliness of care for children presenting with these acute pain crises. These evidence-based guidelines are infrequently followed, resulting in increased pain and hospitalizations. In additional to other barriers to following the guideline, structural racism has been proposed as a significant contributor and the New England Journal of Medicine recently called for the institution of SCD-specific pain management protocols to combat structural racism and reduce time to opioid administration. The investigators' long-term goal is to improve the care and health outcomes of children with acute painful vaso-occlusive crisis treated in the emergency department. The overall aim of the investigators is to test a care pathway using multifaceted implementation strategies to increase guideline adherent care for children in the emergency department with acute painful vaso-occlusive crisis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: Care pathway
Implementation of care pathway as part of hybrid type 2 implementation effectiveness study
Timeliness of receipt of opioids
The percent of patients who receive first dose of opioids within 60 minutes of arrival and subsequent doses within 30 minutes of previous dose
Time frame: A maximum of about 6 hours as all opioids received during the ED stay will be captured
Median time to opioids
Median time from arrival to first opioid and then subsequent opioids
Time frame: A maximum of about 6 hours as all opioids received during the ED stay will be captured
Percent of children hospitalized
Disposition of hospitalization or discharge home
Time frame: A maximum of about 6 hours as that is the typical maximum time to disposition for patients
Plan to share: No — Outcome data gathered through central data Registry. It is a limited dataset. A public use dataset will be made available after the study consistent with NIH guidelines.
No publications or documents are linked to this record.
Started Sep 2021 (actual). Primary completion is estimated for Aug 2026, 59 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical College of Wisconsin →